Status:
COMPLETED
Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less
Lead Sponsor:
University Health Network, Toronto
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Curative-intent therapies for hepatocellular carcinoma (HCC) include radiofrequency ablation (RFA), liver resection (LR), and liver transplantation (LT). Controversy exists in treatment selection for ...
Eligibility Criteria
Inclusion
- Adult (≥18 years) patients
- Solitary HCC ≤ 3cm
- Receipt of either radiofrequency ablation, liver resection, or listing for a liver transplant
- Treatment received between Feb-2000 and Nov-2018
Exclusion
- Pathology other than hepatocellular carcinoma (HCC)
- Receipt of prior treatment (i.e., not treatment naive)
- Not eligible for all of the three treatments (ablation, liver resection, or liver transplant listing)
- Platelet count \<100,000 before treatment
- Alpha-1 fetoprotein (AFP) level \> 1000 before treatment
- Age \> 70 years
- Child-Pugh score C
- Esophageal varices grade greater than 2
- Model for End-stage Liver Disease (MELD) score before treatment exceeding 15
- Presence of ascites pretreatment
- Presence of encephalopathy pretreatment
- Spleen size greater than 12 cm
Key Trial Info
Start Date :
February 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2021
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT05193253
Start Date
February 1 2000
End Date
December 21 2021
Last Update
January 18 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.